|1.||Plotkine, Michel: 3 articles (06/2010 - 12/2003)|
|2.||Genovese, Tiziana: 3 articles (11/2006 - 02/2005)|
|3.||Muià, Carmelo: 3 articles (11/2006 - 02/2005)|
|4.||Mazzon, Emanuela: 3 articles (11/2006 - 02/2005)|
|5.||Cuzzocrea, Salvatore: 3 articles (11/2006 - 02/2005)|
|6.||Cinel, Ismail: 3 articles (05/2005 - 08/2002)|
|7.||Cinel, Leyla: 3 articles (05/2005 - 08/2002)|
|8.||El-Hamoly, Tarek: 2 articles (09/2015 - 01/2014)|
|9.||El-Denshary, Ezzeddin S: 2 articles (09/2015 - 01/2014)|
|10.||El-Ghazaly, Mona A: 2 articles (09/2015 - 01/2014)|
12/01/2010 - "Effects of 3-aminobenzamide on unilateral testicular ischemia-reperfusion injury: what is the role of PARP inhibition?"
01/01/2006 - "Effect of 3-aminobenzamide on Bcl-2, Bax and AIF localization in hippocampal neurons altered by ischemia-reperfusion injury. "
08/01/2004 - "We investigated the efficacy of a cardioplegic solution containing a PARS inhibitor, 3-aminobenzamide (3-AB), for myocardial protection against ischemia-reperfusion injury caused by cardioplegic arrest. "
05/01/2012 - "Increased poly(ADP-ribosyl)ation in peripheral leukocytes and the reperfused myocardium tissue of rats with ischemia/reperfusion injury: prevention by 3-aminobenzamide treatment."
01/01/2009 - "3-aminobenzamide, a poly ADP ribose polymerase inhibitor, attenuates renal ischemia/reperfusion injury."
02/01/2001 - "A statistically significant reduction in the postischemic compound action potential threshold shift was observed in the animals treated with 3-aminobenzamide after 15 or 30 minutes of ischemia, whereas no statistical difference was found after 60 minutes of ischemia. "
01/01/2006 - "Our previous histological and ultrastructural studies showed that PARP inhibitor 3-aminobenzamide (3-AB) protected neurons against death after ischemia. "
05/01/2005 - "The objective of this study was to investigate the effects of 3-aminobenzamide (3-AB) on tissue damage in lung after hind limb ischemia-reperfusion (I/R), by assessing blood biochemical assay and histopathological analysis. "
07/01/2013 - "The hearts were reperfused after 21 minutes of ischemia with a bolus injection of 3-aminobenzamide (3-AB) (10 mg/kg) followed by continuous 3-AB infusion (50 μM) for the whole reperfusion period or for the first 6 minutes or without 3-AB. "
09/01/2004 - "Effects 3-aminobenzamide on ultrastructure of hippocampal CA1 layer after global ischemia in gerbils."
07/01/1997 - "9. In conclusion, our study demonstrates that the PARS inhibitor 3-aminobenzamide exerts multiple protective effects in splanchnic artery occlusion/reperfusion shock. "
11/01/2014 - "Thus, we designed a study to evaluate the efficacy of 3-aminobenzamide (3-AB), a PARP inhibitor, against extracorporeal shock wave induced renal injury. "
12/01/2000 - "Treatment of the cells with 3-aminobenzamide, an inhibitor of PARS, exerted the effects similar to those of heat shock treatment. "
07/01/1997 - "The vascular endothelium is likely to represent an important cellular site of protection by 3-aminobenzamide in SAO shock."
07/01/1997 - "Using 3-aminobenzamide, an inhibitor of PARS, we investigated the role of PARS in the pathogenesis of splanchnic artery occlusion shock. "
01/01/2002 - "A similar protective effect was achieved by PARP inhibition using 3-aminobenzamide, the pharmacologic efficacy of which was confirmed by a marked attenuation of meningitis-induced poly(ADP)ribose formation. "
06/01/2001 - "Increased cerebral cortical cell membrane lipid peroxidation products (conjugated dienes) and decreased brain ATP/phosphocreatine levels observed in the meningitis group were also significantly improved with 3-aminobenzamide treatment. "
06/01/2001 - "3-Aminobenzamide, given 30 mg kg(-1) as a bolus i.v. injection 30 min before induction of meningitis, significantly attenuated the meningitis-induced acute inflammatory responses such as increased cerebrospinal fluid (CSF) lactate concentration, CSF leukocytosis and increased CSF tumor necrosis factor-alpha level. "
12/01/2006 - "Inhibitor of PARP-1, 3-aminobenzamide (30 mg/kgb.w., i.p.), protected the brain against prooxidative and cell death processes, suggesting involvement of PARP-1 in systemic inflammation-related processes in the brain."
01/01/2013 - "This study was conducted to elucidate two questions: first, whether the activation of PARP and NF-κB mediates the renal inflammation secondary to the lipopolysaccharide (LPS)-induced acute lung inflammation; second, whether a PARP inhibitor, 3-aminobenzamide (3-AB), attenuates lung and kidney inflammation by inhibiting NF-κB-dependent proinflammatory cytokines. "
01/19/1998 - "Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation."
01/01/1991 - "These data suggest that nicotinamide and 3-aminobenzamide suppress antigen presenting function of class II MHC positive endothelial cells and fibroblasts at the site of tissue inflammation."
08/01/2003 - "In our experimental study, we investigated the protective effect of 3-aminobenzamide (3-AB), the poly (ADP-ribose) synthetase (PARS inhibitor), on the ileal histopathology and the apoptosis in lipopolysaccharide (LPS)-induced inflammation in rats with obstructive jaundice (OJ). "
|1.||Poly Adenosine Diphosphate Ribose
|2.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|4.||Adenosine Triphosphate (ATP)
|9.||Nitric Oxide (Nitrogen Monoxide)
|1.||Heart Transplantation (Grafting, Heart)
|2.||Heterologous Transplantation (Xenotransplantation)